Frank Tacke

University Name

Germany

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Clinical Nutrition

50%

Immunology

50%

Liver Fibrosis

100%

Fatty Liver

100%

Metabolic Biology

50%

Nafld

50%

Inflammatory Biology

50%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles31

Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease

Article Link

Year:

2025

Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply

Article Link

Year:

2025

Dissecting the immune pathogenesis of HBV-ACLF through single-cell multimodal analysis

Article Link

Year:

2025

Immune pathology in paediatric acute hepatitis of unknown origin — uncovering the link to COVID-19

Article Link

Year:

2025

Liver biopsy and acute hepatology in intensive care unit patients

Article Link

Year:

2025

Steatotische Lebererkrankung mit metabolischer Funktionsstörung – die neue Nomenklatur zur Fettleber im deutschen Kontext

Article Link

Year:

2025

Emerging Trends in Patients Hospitalised With Cirrhosis—Aetiologies, Complications and Outcomes Compared to Other Chronic Health Conditions

Article Link

Year:

2025

Immunopathogenic mechanisms and immunoregulatory therapies in MASLD

Article Link

Year:

2025

Reviewing the function of macrophages in liver disease

Article Link

Year:

2025

Faecal Cytolysin is Associated With Worse Survival in Patients With Primary Sclerosing Cholangitis

Article Link

Year:

2025

Hepatic immune regulation and sex disparities

Article Link

Year:

2024

Metabolic reprogramming in liver fibrosis

Article Link

Year:

2024

Impact of non‐selective beta blockers on further decompensation and death in decompensated cirrhosis: Benefit and risk stratification by MELD score

Article Link

Year:

2024

Angiocrine signaling in sinusoidal homeostasis and liver diseases

Article Link

Year:

2024

Impact of peripheral thyroid hormone balance on liver fat: insights from the NutriAct trial

Article Link

Year:

2024

High disease burden and healthcare resource usage in patients with acute porphyria—A population‐based analysis

Article Link

Year:

2024

Liver macrophages revisited: The expanding universe of versatile responses in a spatiotemporal context

Article Link

Year:

2024

Steatotische Lebererkrankung mit metabolischer Funktionsstörung – die neue Nomenklatur zur Fettleber im deutschen Kontext

Article Link

Year:

2024

Exploring the role of macrophages in the pathogenesis of alcohol-associated liver disease

Article Link

Year:

2024

Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?

Article Link

Year:

2024

Mechanisms of organ fibrosis: Emerging concepts and implications for novel treatment strategies.

Article Link

Year:

2023

Painless jaundice with segmental obstructive cholestasis

Article Link

Year:

2023

Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real‐world cohort

Article Link

Year:

2023

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH

Article Link

Year:

2023

Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH)

Article Link

Year:

2023

Limited access to liver transplantation and TIPS despite high mortality, healthcare resource use and costs of cirrhosis in Germany

Article Link

Year:

2023

Use of albumin infusion for cirrhosis-related complications

Article Link

Year:

2023

Somatic mutant clone screening: scan for novel NASH target genes in mouse liver

Article Link

Year:

2023

At the dawn of potent therapeutics for fatty liver disease – introducing the miniseries on promising pharmacological targets for NASH

Article Link

Year:

2023

Hepatic inflammatory responses in liver fibrosis

Article Link

Year:

2023

Editorial: prevalence, progression rates and mortality predictors of non‐alcoholic fatty liver disease reflected by German statutory health insurance data

Article Link

Year:

2020

Collaborators17

Isabella Lurje

Medizinische Fakultät der RWTH Aachen

GERMANY

Georg Lurje

Deputy Director, Head of Liver- and Transplantation Surgery

University Hospital Heidelberg

GERMANY

Tobias Puengel

Charité - Universitätsmedizin Berlin

GERMANY

Aleksander Krag

Odense University Hospital

DENMARK

Scott Friedman

Dean for Therapeutic Discovery

Icahn School of Medicine at Mount Sinai

UNITED STATES

Alexander Zipprich

GERMANY

Jonel Trebicka

GERMANY

Dominik Geisel

Charité

GERMANY

Prakash Ramachandran

Professor of Experimental Hepatology

University of Edinburgh

UNITED KINGDOM

Raphael Mohr

Charité - Universitätsmedizin Berlin

GERMANY

Julian Pohl

Charité - Universitätsmedizin Berlin

GERMANY

Eva Katrin Wirth

GERMANY

Markus Peck‐Radosavljevic

AUSTRIA

Paul Horn

GERMANY

Alexander Wree

Charité - Universitätsmedizin Berlin

GERMANY

Ralf Weiskirchen

Medizinische Fakultät der RWTH Aachen

GERMANY

Thomas Reiberger

Medical University of Vienna

AUSTRIA

How do I reach out?

Meet Kite AI